Nivolumab, an immune checkpoint inhibitor that blocks PD-1, has recently become one of the effective treatment options for many malignancies, including non-small-cell lung cancer, melanoma, renal cell carcinoma, HCC, and the like (7, 13–15). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.